Innocare Doses First Patient in P-II Trial of Soficitinib for Prurigo Nodularis in China

Shots:

• Innocare has dosed the first patient in the global P-II trial of Soficitinib (ICP-332) for the treatment of pts with prurigo nodularis in China
• Soficitinib was also evaluated in the P-II trial for mod. to sev. atopic dermatitis, which showed superior efficacy & favorable safety, with data presented at the AAD’25
• Soficitinib, a selective TYK2 inhibitor in development for T-cell–mediated autoimmune disorders, blocks cytokine signaling (incl. IL-4, IL-13, & IL-31) to alleviate symptoms by reducing neurogenic itch responses & inhibiting skin inflammation

Ref: GlobeNewswire| Image: InnoCare Pharma | Press Release

Related News:- Zenas BioPharma Enters ~$2B Deal with InnoCare Pharma for Three Autoimmune Product Candidates

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com